1-(3-fluoro-5-methoxy-4-(3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)phenyl)-N-methylmethanamine

ID: ALA5281791

Chembl Id: CHEMBL5281791

Max Phase: Preclinical

Molecular Formula: C19H19FN6O

Molecular Weight: 366.40

Associated Items:

Names and Identifiers

Canonical SMILES:  CNCc1cc(F)c(-c2cc3c(-c4cnn(C)c4)n[nH]c3cn2)c(OC)c1

Standard InChI:  InChI=1S/C19H19FN6O/c1-21-7-11-4-14(20)18(17(5-11)27-3)15-6-13-16(9-22-15)24-25-19(13)12-8-23-26(2)10-12/h4-6,8-10,21H,7H2,1-3H3,(H,24,25)

Standard InChI Key:  GUUQXMDBAHSFGF-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5281791

    ---

Associated Targets(Human)

KIT Tclin Stem cell growth factor receptor (10667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT3 Tclin Tyrosine-protein kinase receptor FLT3 (13481 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NTRK1 Tclin Nerve growth factor receptor Trk-A (7922 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAP4K1 Tchem Mitogen-activated protein kinase kinase kinase kinase 1 (947 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 366.40Molecular Weight (Monoisotopic): 366.1604AlogP: 2.89#Rotatable Bonds: 5
Polar Surface Area: 80.65Molecular Species: BASEHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 8.24CX Basic pKa: 9.01CX LogP: 1.20CX LogD: 0.60
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.57Np Likeness Score: -1.17

References

1. Ye Q, Liu K, Ye HF, Pan J, Sokolsky A, Wang A, Zhang K, Hummel JR, Kong L, Behshad E, He X, Conlen P, Stump K, Ye M, Diamond S, Covington M, Yeleswaram S, Atasoylu O, Vechorkin O, Yao W..  (2023)  Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.,  14  (1.0): [PMID:36655125] [10.1021/acsmedchemlett.2c00238]

Source